Zobrazeno 1 - 10
of 266
pro vyhledávání: '"HAIC"'
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 11, Pp 1557-1567 (2024)
Baokun Liu,1,2,* Lujun Shen,3,4,* Wen Liu,5 Zhiyong Zhang,1,2 Jieqiong Lei,1,2 Zhengguo Li,1,2 Qinquan Tan,6 Hengfei Huang,7 Xingdong Wang,1,2 Weijun Fan3,4 1Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Canc
Externí odkaz:
https://doaj.org/article/68f1ceecc9064e9da83ad2a3a2bb908a
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 11, Pp 1473-1479 (2024)
Qi-Feng Chen,1,* Xiong-Ying Jiang,1,2,* Yue Hu,1,* Song Chen,1 Jun-Zhe Yi,1 Sui-Xing Zhong,1 Jiong-Liang Wang,1 Ning Lyu,1 Ming Zhao1 1Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, State Ke
Externí odkaz:
https://doaj.org/article/422b821a6bd645ca83e5b80b895c841c
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundHepatic arterial infusion chemotherapy (HAIC) with the FOLFOX regimen has demonstrated efficacy in patients with unresectable hepatocellular carcinoma (HCC). The combined targeted and immunotherapy has emerged as a first-line treatment for
Externí odkaz:
https://doaj.org/article/62c3b4b384134753badc3944181f844f
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
IntroductionGemcitabine and cisplatin remain the cornerstone for the treatment of advanced or unresectable biliary tract cancers, but the incidence rate of the grade 3 or 4 toxic effects is high (70.7%). In recent years, significant progress has been
Externí odkaz:
https://doaj.org/article/78c61c07cbb54d03891df6cb6f20845f
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundThe five-year recurrence rate for patients with hepatocellular carcinoma (HCC) is as high as 70%. Patients with high-risk recurrence factors experience significantly poorer prognosis. Local regional therapies, including transarterial chemoe
Externí odkaz:
https://doaj.org/article/39ae34dd2ae046468014ce936ec752ba
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background The treatment of hepatocellular carcinoma (HCC) patients exhibiting high-risk characteristics (Vp4, and/or bile duct invasion, and/or tumor occupancy ≥ 50%) lacks standardized approaches and yields unfavorable results. This stud
Externí odkaz:
https://doaj.org/article/9c927101442f4cb8b7a7e954d3e297ac
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundThe first-line treatment for advanced hepatocellular carcinoma has evolved significantly. This study aimed to identify the most beneficial regimen.MethodsA systematic search was conducted from July 2012 to August 2024 across the following f
Externí odkaz:
https://doaj.org/article/cb7e704f2f3b411b821907bcaeeb8787
Autor:
Li-xin Du, Guo-li Sheng, An-da Shi, Kang-shuai Li, Zeng-li Liu, Yong-chang Tang, Yi Liu, Zong-li Zhang
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundHepatocellular carcinoma (HCC) is the most common primary liver cancer and often arises in the context of chronic liver disease, such as hepatitis B or C infection, and cirrhosis. Advanced unresectable HCC (uHCC) presents significant treatm
Externí odkaz:
https://doaj.org/article/44d0ce7a80324cce8cd1a87c32cde748
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
PurposeTo evaluate the efficacy and safety of mFOLFOX-based hepatic arterial infusion chemotherapy (HAIC) combined with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) in the treatment of advanced hepatocellular carcinoma (H
Externí odkaz:
https://doaj.org/article/9104c5e2695341a0b576d6f571adde0e
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThis study aimed to assess the effectiveness and safety of vascular intervention combined with lenvatinib versus vascular intervention alone in the treatment of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT),
Externí odkaz:
https://doaj.org/article/cf9afd8088554c75b18d5af18a3e1af3